Voyager Therapeutics (VYGR) Receivables (2022 - 2026)

Voyager Therapeutics (VYGR) has 5 years of Receivables data on file, last reported at $1.6 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables fell 22.04% year-over-year to $1.6 million; the trailing twelve-month figure through Mar 2026 stood at $1.6 million (down 22.04% YoY), and the FY2025 full-year result was $2.0 million, down 10.5% from the prior year.
• Receivables fell to $1.6 million in Q1 2026, from $1.9 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $83.5 million in Q4 2023 to a low of $1.6 million in Q1 2026.
• A 5-year average of $13.3 million and a median of $3.4 million in 2024 frame the typical range for Receivables.
• Across the five-year window, Receivables plunged 97.39% in 2024 and declined 12.29% in 2025, its largest moves.
• Tracing VYGR's Receivables over 5 years: stood at $10.2 million in 2022, then surged by 716.54% to $83.5 million in 2023, then sank by 97.39% to $2.2 million in 2024, then decreased by 12.29% to $1.9 million in 2025, then retreated by 13.96% to $1.6 million in 2026.
• Business Quant data shows VYGR's Receivables at $1.6 million in Q1 2026, $1.9 million in Q4 2025, and $4.0 million in Q3 2025.